MediciNova (MNOV) Fundamental Analysis: Revenue, Earnings & Valuation

3.70 / 10

Netural

Fundamental assessment scores 3.7/10, indicating concerning quality. Positive factors include Cash‑MV and high inventory turnover, while revenue‑MV, asset‑MV and tax‑to‑profit ratios are weak. Overall health is unfavorable, urging caution despite some constructive metrics.

Analysis Checks(6/10)

Revenue-MV

Value-4.52

Score1/3

Weight12.88%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.33%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.09%

1M Return6.74%

Gross profit margin (%)

Value7.58

Score1/3

Weight-1.21%

1M Return-0.63%

PB-ROE

Value0.34

Score0/3

Weight8.60%

1M Return3.23%

Income tax / Total profit (%)

Value-0.05

Score1/3

Weight-0.99%

1M Return-0.50%

Fixed assets turnover ratio

Value1.42

Score3/3

Weight2.20%

1M Return1.06%

Cost of sales ratio (%)

Value92.42

Score3/3

Weight9.88%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight33.04%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight15.18%

1M Return5.94%

Is MNOV undervalued or overvalued?

MNOV scores 3.70/10 on fundamentals and holds a Fair valuation at present. Backed by its -25.50% ROE, 0.00% net margin, -5.91 P/E ratio, 1.70 P/B ratio, and -4.35% earnings growth, these metrics solidify its Netural investment rating.